NCT01606397已完成1 期
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Doses of LY2409021 in Patients With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Number of participants with one or more drug related adverse events (AEs) or any serious AEs
研究概览
简要总结
The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes :
- The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses
- How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks
- How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal
- How LY2409021 works when given with metformin
- How daily dosing of LY2409021 affects the cells that produce insulin
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be either a male, or a female who cannot become pregnant, who has type 2 diabetes and is either controlling diabetes through diet and exercise, or taking metformin
- •Have an hemoglobin A1c (HbA1c) value at screening of greater than or equal to 6.5% and less than or equal to 10.0% on a stable treatment regimen at the time of measurement
- •Have a screening body mass index (BMI) of 20 to 40 kg/m^2 inclusive
- •Have a blood pressure reading at screening of between 90 to 160 millimeters of mercury (mmHg) (systolic) and 40 to 95 mmHg (diastolic)
排除标准
- •Have used insulin for diabetic control within 1 year of study entry
- •Have used thiazolidinediones within 3 months, or any other drugs for treatment of hyperglycemia (except metformin) within 1 month, prior to first planned dosing. Metformin is acceptable for this study.
- •Have clinically significant coronary artery disease
- •Have clinically significant peripheral vascular disease
- •Have clinical evidence of active diabetic proliferative retinopathy
- •Have known significant autonomic neuropathy as evidenced by urinary retention, orthostatic hypotension, diabetic diarrhea or gastroparesis
- •Impaired renal function (serum creatinine greater than 115 micromoles/liter [μmol/L] [1.3 mg/dL] in women, greater than 130 μmol/L [1.5 mg/dL] in men)
- •Have triglycerides greater than 4.5 millimoles per liter (mmol/L) [approximately 400 mg/dL] at screening
- •Were hospitalized for poor control of diabetes (keto-acidotic episode) in the last 6 months
- •Are allergic to LY2409021 or similar drugs
- •Have history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (other than diabetes), hematological, or neurological disorders capable of significantly altering the absorption, or metabolism or elimination of drugs or of constituting a risk when taking the study medication or interfering with the interpretation of data
- •Have used systemic glucocorticoids within 1 month prior to first dosing
- •Have donated 450 mL or more of blood in the last 3 months or have donated any blood within the last month
- •Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female), or are unwilling to stop alcohol as required by the study restrictions (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo administered orally once daily for 4 weeks
干预措施: Placebo (Drug)
5 mg LY2409021
Experimental
5 mg LY2409021 administered orally once daily for 4 weeks
干预措施: LY2409021 (Drug)
30 mg LY2409021
Experimental
30 mg LY2409021 administered orally once daily for 4 weeks
干预措施: LY2409021 (Drug)
60 mg LY2409021
Experimental
60 mg LY2409021 administered orally once daily for 4 weeks
干预措施: LY2409021 (Drug)
90 mg LY2409021
Experimental
90 mg LY2409021 administered orally once daily for 4 weeks
干预措施: LY2409021 (Drug)
结局指标
主要结局
Number of participants with one or more drug related adverse events (AEs) or any serious AEs
时间窗: From first dose of study drug up to discharge (at least 28 days after last dose)
次要结局
- Pharmacokinetics: Area under the concentration curve (AUC) of LY2409021(From first study drug dose to Day 28 post last dose)
- Pharmacokinetics: Maximum concentration (Cmax) of LY2409021(From first study drug dose to Day 28 post last dose)
- Change in fasting blood glucose level(From Day -1 to Day 28 of dosing)
- Change in incremental area under the curve (AUC) for glucose(From Day -1 to Day 28 of dosing)
- Change in homeostasis model assessment of beta cell function (HOMA-B)(From baseline to Day 28)
- Change in fasting glucagon level(From Day -1 to Day 28 of dosing)
- Change in fasting insulin level(From Day -1 to Day 28 of dosing)
- Change in fasting C-peptide level(From Day -1 to Day 28 of dosing)
- Change in fasting glucagon-like peptide-1 (GLP-1) level(From Day -1 to Day 28 of dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus PatientsDiabetes Mellitus, Type 2NCT01253278Eli Lilly and Company38
已完成
1 期
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.Diabetes Mellitus, Type IINCT01301092Eli Lilly and Company30
已完成
1 期
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01606371Eli Lilly and Company32
终止
2 期
A Study of LY2409021 in Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT02111096Eli Lilly and Company174
已完成
2 期
A Study of LY2409021 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01241448Eli Lilly and Company263